Press release from Business Wire
Biosense Webster Showcases Cutting Edge Innovation and Leadership in AF Ablation at HRS Annual Scientific Sessions 2013
Wednesday, May 08, 2013
Biosense Webster Showcases Cutting Edge Innovation and Leadership in AF Ablation at HRS Annual Scientific Sessions 201308:50 EDT Wednesday, May 08, 2013
DIAMOND BAR, Calif. (Business Wire) -- Biosense Webster, Inc., a worldwide leader in the diagnosis and treatment of cardiac arrhythmias, will showcase its portfolio of cutting edge innovative technologies and its unrivaled leadership in atrial fibrillation ablation at the 2013 Heart Rhythm Society's 34th Annual Scientific Sessions in Denver. This meeting draws experts in cardiac rhythm management from around the globe to explore the therapeutics and technologies shaping the future of this dynamic field.
The company will demonstrate its leadership at this meeting with a complete portfolio of market-leading technologies and innovative solutions for Electrophysiologists and Allied Health Professionals. The company's full array of support for physicians and their patients includes Clinical Support, Global Education and Training Programs, Technical Service, Patient Education, and other resources to support the expanded access to ablation treatment.
Speaking about the event, Shlomi Nachman, Worldwide President, Biosense Webster, said, “We are excited to meet with our physician colleagues from around the world and demonstrate our commitment to them and to their patients. Biosense Webster stands alone in our singular focus on advancing EP ablation, and our commitment to improving the lives of patients suffering from atrial fibrillation.”
Among the highlights Biosense Webster will unveil for meeting attendees are:
Introduction of the Biosense Webster
Fluoroscopy Reduction Program
The Biosense Webster Fluoroscopy Reduction Program takes the advances of the CARTO® 3 System to the next level. It enables Electrophysiologists to measure, track, evaluate and compare fluoroscopy time and provides resources to become more completely informed about the opportunities to reduce unnecessary radiation exposure during cardiac ablation procedures. This industry-leading initiative incorporates continuous learning focused on fluoroscopy reduction and specialized programs to involve lab staff, while fostering knowledge sharing among physicians.
The Biosense Webster Fluoroscopy Reduction Program leverages innovative techniques to optimize the use of existing tools such as the CARTO® 3 System with its CARTOSOUND® Module as well as new technologies including CARTOUNIVU™ Module, CARTO® System MEM version with the PENTARAY® NAV Catheter and THERMOCOOL® SF Catheter with Curve Visualization.
Results of the SMART-AF Trial:
of Symptomatic Paroxysmal Atrial Fibrillation Using Novel Contact
Andrea Natale, MD, Executive Medical Director of the Texas Cardiac Arrhythmia Institute at St. David's Medical Center and a member of the SMART-AF study advisory committee, will present the 12-month safety and effectiveness results from this IDE pivotal study which enrolled 172 subjects at 21 leading centers across the United States. The trial investigated the use of the THERMOCOOL® SMARTTOUCH™ Catheter* with contact force (CF) sensing technology for the ablation of symptomatic paroxysmal atrial fibrillation.
Dr. Natale will present results during the Late Breaking Clinical Trials II session on Friday May 10 at 2 p.m. in Four Seasons Ballroom 1 at the Colorado Convention Center in Denver.
Launch of the All-New Biosensewebster.com
The new www.Biosensewebster.com offers customers a new, richer online experience to engage with Biosense Webster. Expanded to serve the needs of the broad spectrum of Biosense Webster customers, the new site features enhanced navigation and extensive product information including videos, guides and other resources.
About AF and cardiac ablation
Atrial Fibrillation is the most prevalent arrhythmia, and is a leading cause of stroke among people 65 years and older. Worldwide, it is estimated that 20 million people have AF, yet only ~130,000 are treated with ablation every year. The public health implications of AF are a growing concern because those with AF are at an increased risk of morbidity and mortality as well as a reduced quality of life.
Most patients with AF today are treated with anti-arrhythmic drugs (AADs), even though about half of them are refractory to these drugs. During cardiac ablation, energy is delivered through the catheter to those areas of the heart muscle causing the abnormal heart rhythm. This energy “disconnects” the pathway of the abnormal rhythm. Cardiac ablation is commonly used for “simple” arrhythmias, like Wolff-Parkison-White Syndrome and atrioventricular nodal re-entry tachycardia (AVNRT), and is increasingly being used for more complex arrhythmias like ventricular tachycardia and atrial fibrillation. THERMOCOOL® Navigation Catheters are approved for drug refractory recurrent symptomatic paroxysmal atrial fibrillation, when used with CARTO® Systems (excluding NAVISTAR® RMT THERMOCOOL® Catheter).
About Biosense Webster, Inc.
Biosense Webster, Inc., part of the Johnson & Johnson Family of Companies, pioneered EP diagnostic catheters more than 20 years ago and continues to lead the industry as an innovative provider of advanced cardiac diagnostic, therapeutic, and mapping tools. As the leader in EP navigation systems and ablation therapy, Biosense Webster, Inc. has technology that includes the largest installed base of cardiac mapping navigation systems worldwide in leading hospitals and teaching institutions. For more information about Biosense Webster and its products, please visit: www.biosensewebster.com (this site is intended for US visitors only).
* The THERMOCOOL® SMARTTOUCH™ Catheter is approved for investigational use only and is not for sale in the United States.
Dr. Natale is compensated for his services as a member of the company's scientific advisory board and provides other consulting services.
Biosense Webster, Inc.
Sandy Pound, 732-524-1941